Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. Its research and development pipeline includes RAS(ON) inhibitors that bind to RAS variants, used as monotherapy or in combination with other RAS(ON) inhibitors, RAS companion inhibitors, or other therapeutic agents. Key drug candidates include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805). The company is also developing RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). Revolution Medicines is headquartered in Redwood City, California, and was incorporated in 2014.

Revolution Medicines, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol RVMD. The trading currency for its shares is the United States Dollar (USD). As a US-based company, its stock is traded in USD, and investors typically use US dollars to buy and sell shares on the Nasdaq exchange.

Revolution Medicines operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for cancer, particularly RAS-addicted cancers. Biotechnology firms like Revolution Medicines engage in research and development of drugs and treatments, often at the clinical stage, before potential regulatory approval and commercialization.

Revolution Medicines is headquartered in Redwood City, California, United States. The company primarily serves the US market, as indicated by its country and region designation. While its clinical trials and operations are based in the US, the company's therapies aim to address global healthcare needs, particularly for patients with RAS-addicted cancers. The headquarters location in California places it within a major biotechnology hub, providing access to talent and research resources.

Revolution Medicines' pipeline includes several RAS(ON) inhibitors. Daraxonrasib (RMC-6236) and zoldonrasib G12D (RMC-9805) are in a phase 3 registrational trial for first-line pancreatic ductal adenocarcinoma (1L PDAC). Elironrasib G12C (RMC-6291) is in early clinical development for solid tumors. Additionally, the company has development candidates RMC-5127 (G12V) and RMC-0708 (Q61H) in clinical trials, and RMC-8839 (G13C) in preclinical stages. These therapies target specific RAS mutations, aiming to provide precision treatments for cancer patients.